← Eichor
Condition: Cd19 Negative B Cell Malignancies Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cd19 Negative B Cell Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528CAR-T Immunotherapy Targeting CD19- ALL
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT040161294SCAR-T Therapy Post CD19-targeted Immunotherapy
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04430530Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymph
Phase 1 · 1 location(s) · Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · NCT07369492
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.